Acadia shares skid as Nuplazid clears mid-stage hurdle for Alzheimer’s psychosis, but skeptics pounce
Shares of San Diego-based Acadia Pharmaceuticals $ACAD shot up this morning after the company scored a success in a mid-stage study of its 5-HT2A -targeting drug Nuplazid (pimavanserin) in Alzheimer’s disease psychosis. But the biotech also had to face off against some expert opinion that was not in the least bit impressed by the results, especially factoring in a failed secondary endpoint that forced shares to slide back in the backlash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
